Analyst firms · Morgan Stanley · QGEN
Morgan Stanley QGEN price target and rating history
Qiagen N.V. (QGEN) · Health Care
Morgan Stanley rates Qiagen N.V. (QGEN) Overweight with a $42 price target, as of its latest action on Jun 23, 2026. It has published 4 rating actions on QGEN since October 2022, including 2 upgrades and 1 downgrade. Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Morgan Stanley's $42 is 9% below that.
- Current rating
- Overweight
- Price target
- $42
- Median target, all firms
- $46.25
- Actions on QGEN
- 4
Morgan Stanley price target on QGEN
Every Morgan Stanley rating on QGEN
- Jun 23, 2026
- Jan 6, 2025
- May 23, 2023
- Oct 18, 2022
How other firms rate QGEN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $55 | Oct 6, 2026 |
| UBS | Neutral | $47 | Sep 9, 2026 |
| Berenberg | Hold | $45.50 | Jul 14, 2026 |
| Kepler Cheuvreux | Hold | $38.60 | Jun 25, 2026 |
| Morgan Stanley | Overweight | $42 | Jun 23, 2026 |
| Robert W. Baird | Outperform | $43 | Apr 29, 2026 |
| Deutsche Bank | Buy | $54 | Mar 13, 2026 |
| Citigroup | Neutral | $50 | Dec 11, 2025 |
Questions about Morgan Stanley and QGEN
- What is Morgan Stanley's price target for QGEN?
- Morgan Stanley's latest stated price target for Qiagen N.V. (QGEN) is $42, from its action on Jun 23, 2026.
- What is Morgan Stanley's rating on QGEN?
- Morgan Stanley rates QGEN Overweight, a bullish rating, as of Jun 23, 2026.
- When did Morgan Stanley last change its view on QGEN?
- On Jun 23, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $42.
- How does Morgan Stanley's QGEN target compare with other analysts?
- Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Morgan Stanley's $42 is 9% below that.
More QGEN rating histories
All Morgan Stanley ratingsQGEN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.